Rheumatology (Oxford):PACNS成人患者:维持治疗有益于长期结局

2017-11-16 吴星 环球医学

原发性中枢神经系统血管炎(PACNS)是一种罕见、病因尚不明确的血管炎。2017年10月,发表在《Rheumatology (Oxford)》的一项长期随访研究调查了诱导后维持治疗对PACNS成人患者结局的影响。结果表明,成人PACNS维持治疗与较好的功能结局和较低的复发率相关。

原发性中枢神经系统血管炎(PACNS)是一种罕见、病因尚不明确的血管炎。2017年10月,发表在《Rheumatology (Oxford)》的一项长期随访研究调查了诱导后维持治疗对PACNS成人患者结局的影响。结果表明,成人PACNS维持治疗与较好的功能结局和较低的复发率相关。

目的:研究者旨在分析诱导后维持治疗对PACNS成人患者结局的影响。

方法:研究者分析了在法国多中心PACNS队列中登记患者的长期结局(复发、生存和功能状态),这些患者诱导治疗后获得缓解并根据是否接受维持治疗随访12个月。好的结局定义为最终随访时无复发生存和功能状态较好(改良的Rankin量表≤2)。

结果:对97例患者[46例(47%)为女性,确诊时中位年龄为46(18~78))岁]随访中位55(5~198)个月。诱导治疗中95例(98%)患者使用糖皮质激素, 80例(83%)患者联合使用了免疫抑制剂,大部分为CYC。48例(49%)患者处方为维持治疗,其中42例伴随CYC。糖皮质激素启用后4(3~18)个月,开始使用维持治疗。在最后一次随访时,接受维持治疗的患者中32例(67%)结局较好vs没有接受维持治疗的患者中10例(20%)结局较好(P<0.0001)。32例(33%)患者复发[10例接受维持治疗,22例(45%)未接受维持治疗,P = 0.01];4例患者在复发后死亡。在多变量分析中,维持治疗是结局较好的唯一独立预测因素[比值比(OR)= 7.8(95% CI:3.21~20.36),P<0.0001]。

结论:该长期随访研究的结局显示,成人PACNS维持治疗与较好的功能结局和较低的复发率相关。需要进一步的研究来证实这些结果。

原始出处:

de Boysson H, Parienti JJ, Arquizan C, et al. Maintenance therapy is associated with better long-term outcomes in adult patients with primary angiitis of the central nervous system. Rheumatology (Oxford). 2017 Oct 1;56(10):1684-1693. doi: 10.1093/rheumatology/kex047.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972860, encodeId=11b519e28609e, content=<a href='/topic/show?id=1a911356535' target=_blank style='color:#2F92EE;'>#Oxford#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13565, encryptionId=1a911356535, topicName=Oxford)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Jul 26 22:01:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062527, encodeId=7eed206252e3e, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Sep 22 09:01:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914237, encodeId=56fd191423e89, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Feb 03 07:01:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385097, encodeId=afb0138509e9a, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515235, encodeId=e897151523595, content=<a href='/topic/show?id=c38213655bb' target=_blank style='color:#2F92EE;'>#PACNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13655, encryptionId=c38213655bb, topicName=PACNS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a6210745970, createdName=ms3830150583600765, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972860, encodeId=11b519e28609e, content=<a href='/topic/show?id=1a911356535' target=_blank style='color:#2F92EE;'>#Oxford#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13565, encryptionId=1a911356535, topicName=Oxford)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Jul 26 22:01:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062527, encodeId=7eed206252e3e, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Sep 22 09:01:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914237, encodeId=56fd191423e89, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Feb 03 07:01:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385097, encodeId=afb0138509e9a, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515235, encodeId=e897151523595, content=<a href='/topic/show?id=c38213655bb' target=_blank style='color:#2F92EE;'>#PACNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13655, encryptionId=c38213655bb, topicName=PACNS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a6210745970, createdName=ms3830150583600765, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972860, encodeId=11b519e28609e, content=<a href='/topic/show?id=1a911356535' target=_blank style='color:#2F92EE;'>#Oxford#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13565, encryptionId=1a911356535, topicName=Oxford)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Jul 26 22:01:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062527, encodeId=7eed206252e3e, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Sep 22 09:01:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914237, encodeId=56fd191423e89, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Feb 03 07:01:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385097, encodeId=afb0138509e9a, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515235, encodeId=e897151523595, content=<a href='/topic/show?id=c38213655bb' target=_blank style='color:#2F92EE;'>#PACNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13655, encryptionId=c38213655bb, topicName=PACNS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a6210745970, createdName=ms3830150583600765, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
    2018-02-03 lg.zhao
  4. [GetPortalCommentsPageByObjectIdResponse(id=1972860, encodeId=11b519e28609e, content=<a href='/topic/show?id=1a911356535' target=_blank style='color:#2F92EE;'>#Oxford#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13565, encryptionId=1a911356535, topicName=Oxford)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Jul 26 22:01:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062527, encodeId=7eed206252e3e, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Sep 22 09:01:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914237, encodeId=56fd191423e89, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Feb 03 07:01:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385097, encodeId=afb0138509e9a, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515235, encodeId=e897151523595, content=<a href='/topic/show?id=c38213655bb' target=_blank style='color:#2F92EE;'>#PACNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13655, encryptionId=c38213655bb, topicName=PACNS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a6210745970, createdName=ms3830150583600765, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1972860, encodeId=11b519e28609e, content=<a href='/topic/show?id=1a911356535' target=_blank style='color:#2F92EE;'>#Oxford#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13565, encryptionId=1a911356535, topicName=Oxford)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/WQ1WyMBGic8d2fKdCe6Cm3vaRh4X8YnlumYndC46iagNCBl9Df8RtoCaQchnFtZldHUctGJjsgsyutUlu8vPq6yQ/132, createdBy=97862500016, createdName=ms3117646317107274, createdTime=Thu Jul 26 22:01:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2062527, encodeId=7eed206252e3e, content=<a href='/topic/show?id=872c15438a4' target=_blank style='color:#2F92EE;'>#Rheumatology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15438, encryptionId=872c15438a4, topicName=Rheumatology)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Sep 22 09:01:00 CST 2018, time=2018-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1914237, encodeId=56fd191423e89, content=<a href='/topic/show?id=4b8349356f' target=_blank style='color:#2F92EE;'>#CNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4935, encryptionId=4b8349356f, topicName=CNS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c737344, createdName=lg.zhao, createdTime=Sat Feb 03 07:01:00 CST 2018, time=2018-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1385097, encodeId=afb0138509e9a, content=<a href='/topic/show?id=99d99e03311' target=_blank style='color:#2F92EE;'>#长期结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97033, encryptionId=99d99e03311, topicName=长期结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2c31495, createdName=liuyg0228, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515235, encodeId=e897151523595, content=<a href='/topic/show?id=c38213655bb' target=_blank style='color:#2F92EE;'>#PACNS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13655, encryptionId=c38213655bb, topicName=PACNS)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a6210745970, createdName=ms3830150583600765, createdTime=Sat Nov 18 06:01:00 CST 2017, time=2017-11-18, status=1, ipAttribution=)]

相关资讯

Autoimmun Rev:血管炎孕妇的妊娠结局

系统性血管炎(SV)是一种非常见疾病,在育龄期的女性很少出现该疾病,因此目前临床上关于该疾病女性妊娠的数据极少,只有少部分回顾性的资料。因此Fredi M等人对该病发生在妊娠前、妊娠期、妊娠后时候的母儿结局做了项研究。

Circulation:川崎病的诊断、治疗和长期管理——AHA医疗卫生人员的科学声明

川崎病是一种儿童时期的急性血管炎,在约25%的未治疗病例中,可造成冠状动脉瘤。在发达国家,已经广泛对其报道,并且成为发达国家儿童获得性心脏病的主要原因。2017年4月,发表在《Circulation》的一项美国心脏病协会卫生专业人员的科学声明阐述了川崎病的诊断、治疗和长期管理。

Lancet:发热原因待查——案例报道

患者男,30岁,2014年3月,因发热10天,最高达40°C,伴出汗、寒战、头痛就诊,几个月时间里患者的体重莫名其妙的下降了10公斤。 患者既往体检,否认旅游史。 查体:CRP升高(CRP, 180 mg/L),其他血液检查正常(包括抗核抗体、抗可提取性核抗原抗体、抗中性粒细胞胞浆抗体(ANCA)、内分泌检查、艾滋病病毒、巨细胞病毒、乙型肝炎和丙型肝炎),血、尿、脑脊液培养没有发现病毒

高手来,打死我也想不到是这个病——案例报道

患者男,48岁,因“复发性腹痛和便血”就诊。 15年前使用干扰素α治疗基因1型丙型肝炎病毒(HCV);不过治疗失败,并没有清除掉病毒。5年前因膜性增生性肾小球肾炎,出现肾功能不全,自此以后,一直使用强的松和环孢素治疗。6个月前因为腿部紫癜和腹痛就诊外院,此后使用达卡他韦+阿那匹韦治疗HCV,但是腹痛加重,且出现血便,随后转入我院。 查体:左上腹部疼痛,有触痛,腿水肿,有紫癜(A

Lancet:Tocilizumab治疗巨细胞动脉炎的有效性

背景:巨细胞动脉炎是一种免疫介导的大中动脉疾病,常影响50岁以上人群。糖皮质激素治疗是金标准,可预防严重血管并发症,但也与大量的死亡率和发病率相关。托珠单抗(Tocilizumab),一种抗人白介素6(IL-6)受体抗体,可快速反应并缓解巨细胞动脉炎。我们开展了首个随机临床试验研究tocilizumab在新近诊断或复发性巨细胞动脉炎患者中的安全性和有效性。方法:单中心,随机,双盲,安慰剂对照试验,

NEJM:应用可卡因药物致上腭部破坏性病变-案例报道

男性,44岁,头痛1年余和患有额叶综合征应用可卡因药物止痛。常规体格检查可见其眼肌麻痹,眼球运动受限,轻度单侧(右侧)锥体束征,上腭部溃疡(如图A)。CT检查结果显示鼻腔软骨结构出现广泛破坏(如图B)。磁共振成像结果显示额叶广泛水肿(如图C),脑膜与额叶信号广泛增强(如图C)。实验室检查结果显示抗中性粒细胞胞浆抗体血清试验阳性(ANCA)。细菌和真菌培养结果为阴性。组织病理学检查显示慢性炎症,而这